

MDwerks, Inc.
Form 10QSB
November 13, 2007

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Form 10-QSB

(Mark One)

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2007

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT

For the transition period from _____ to _____

Commission File Number: 333-118155

MDWERKS, INC.

(Exact name of small business issuer as specified in charter)

Delaware

(State or other jurisdiction of
incorporation or organization)

33-1095411

(I.R.S. Employer
Identification No.)

Windolph Center, Suite I

1020 N.W. 6th Street

Deerfield Beach, FL 33442

(Address of principal executive offices)(Zip Code)

(954) 389-8300

(Issuer's telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date: 12,940,065 shares at November 9, 2007

Transitional Small Business Disclosure Format (Check one): Yes No

MDWERKS, INC.
FORM 10-QSB
FOR THE PERIOD ENDED SEPTEMBER 30, 2007

INDEX

| | Page |
|----------------------------------------------------------------------------------------------------------------------|-------------|
| PART I - FINANCIAL INFORMATION | |
| Item 1 - Consolidated Financial Statements | |
| Consolidated Balance Sheet As of September 30, 2007 (Unaudited) | 3 |
| Consolidated Statements of Operations (Unaudited) For the Three and Nine Months Ended September 30, 2007 and 2006 | 4 |
| Consolidated Statements of Cash Flows (Unaudited) For the Nine Months Ended September 30, 2007 and 2006 | 5 |
| Notes to Unaudited Consolidated Financial Statements | 6-21 |
| Item 2 - Management's Discussion and Analysis and Plan of Operations | 22-29 |
| Item 3 - Controls and Procedures | 29-30 |
| PART II - OTHER INFORMATION | |
| Item 1 - Legal Proceedings | 31 |
| Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds | 31 |
| Item 3 - Defaults Upon Senior Securities | 31 |
| Item 4 - Submission of Matters to a Vote of Security Holders | 31 |
| Item 5 - Other Information | 31 |
| Item 6 - Exhibits | 31 |

MDWERKS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEET
SEPTEMBER 30, 2007
(Unaudited)

| ASSETS | |
|-----------------------------------------------------------------------------------------------------|---------------------|
| Current assets: | |
| Cash | \$ 1,771,111 |
| Notes receivable | 1,010,549 |
| Accounts receivable | 82,056 |
| Prepaid expenses and other | 48,017 |
| Total current assets | 2,911,733 |
| Long-term assets: | |
| Property and equipment, net of accumulated depreciation of \$81,724 | 127,173 |
| Debt issuance and offering costs, net of accumulated amortization of \$200,295 | 470,057 |
| Total assets | \$ 3,508,963 |
| LIABILITIES AND STOCKHOLDERS' DEFICIENCY | |
| Current liabilities: | |
| Current portion of notes payable, net | \$ 1,686,269 |
| Mandatory Redeemable Convertible Series B Preferred Stock, \$.001 par value, 250 shares authorized; | |
| 200 shares issued and outstanding | 1,126,831 |
| Loans payable | 319,559 |
| Accounts payable | 461,569 |
| Accrued expenses | 468,295 |
| Deferred revenue | 10,996 |
| Total current liabilities | 4,073,519 |
| Long-term liabilities: | |
| Notes payable, net of discount of \$2,829,535, less current portion | 391,809 |
| Deferred revenues, less current portion | 6,237 |
| Total liabilities | 4,471,565 |
| Stockholders' deficiency: | |
| Preferred stock, \$.001 par value, 10,000,000 shares authorized; | |
| no shares issued and outstanding | — |
| Series A preferred stock, \$.001 par value, 1,000 shares authorized; | |
| 2 shares issued and outstanding | — |
| Common stock, \$.001 par value, 100,000,000 shares authorized; | |
| 12,940,065 shares issued and outstanding | 12,940 |
| Additional paid-in capital | 32,980,978 |
| Accumulated deficit | (33,867,842) |
| Deferred compensation | (88,678) |
| Total stockholders' deficiency | (962,602) |
| Total liabilities and stockholders' deficiency | \$ 3,508,963 |

The accompanying notes should be read in conjunction with the unaudited consolidated financial statements

MDWERKS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS

| | For the Three Months Ended September 30, | | For the Nine Months Ended September 30, | |
|--------------------------------------------------------------------|---------------------------------------------|---------------------|--------------------------------------------|---------------------|
| | 2007 (Unaudited) | 2006 (Unaudited) | 2007 (Unaudited) | 2006 (Unaudited) |
| Revenue: | | | | |
| Service fees | \$ 119,820 | \$ 147,726 | \$ 356,540 | \$ 262,292 |
| Financing income | 16,753 | 10,387 | 46,693 | 36,558 |
| Total revenue | 136,573 | 158,113 | 403,233 | 298,850 |
| Operating expenses: | | | | |
| Compensation | 1,229,568 | 1,730,160 | 4,073,320 | 3,193,895 |
| Consulting expenses | 158,360 | 144,081 | 562,798 | 399,126 |
| Professional fees | 74,215 | 153,782 | 299,901 | 277,906 |
| Selling, general and administrative | 372,161 | 456,587 | 1,260,775 | 1,416,993 |
| Total operating expenses | 1,834,304 | 2,484,610 | 6,196,794 | 5,287,920 |
| Loss from operations | (1,697,731) | (2,326,497) | (5,793,561) | (4,989,070) |
| Other income (expense): | | | | |
| Interest income | 13,492 | 1,123 | 60,201 | 5,671 |
| Interest expense | (500,601) | (372,291) | (1,526,737) | (380,039) |
| Gain (Loss) on revaluation of warrant liability | — | 1,030,338 | — | (192,914) |
| Other income (expense) | — | (3,502) | 165 | (3,491) |
| Total other income (expense) | (487,109) | 655,668 | (1,466,371) | (570,773) |
| Net loss | (2,184,840) | (1,670,829) | (7,259,932) | (5,559,843) |
| Deemed preferred stock dividend | — | — | — | (913,777) |
| Common stock issued in connection with anti-dilutive recalculation | — | — | — | (246,240) |
| Net loss attributable to common shareholders | \$ (2,184,840) | \$ (1,670,829) | \$ (7,259,932) | \$ (6,719,860) |
| NET LOSS PER COMMON SHARE - basic and diluted | \$ (0.17) | \$ (0.14) | \$ (0.57) | \$ (0.57) |
| WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING - basic and diluted | 12,907,674 | 11,777,818 | 12,726,732 | 11,728,751 |

The accompanying notes should be read in conjunction with the unaudited consolidated financial statements

MDWERKS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

| | For the Nine Months Ended September 30, | |
|-----------------------------------------------------------------------------|--------------------------------------------|---------------------|
| | 2007 (Unaudited) | 2006 (Unaudited) |
| Cash flows from operating activities: | | |
| Net loss | \$ (7,259,932) | \$ (5,559,843) |
| Adjustments to reconcile net loss to net cash used in operating activities: | | |
| Depreciation | 34,168 | 22,807 |
| Amortization of debt issuance cost | 10,954 | 3,120 |
| Amortization of debt discount | 1,208,594 | 28,793 |
| Amortization of deferred offering costs | 133,500 | — |
| Amortization of deferred compensation | 199,530 | — |
| Stock-based compensation | 2,506,281 | 1,878,572 |
| Common stock issued for services | 150,000 | 285,000 |
| Settlement expense related to debt conversion | — | 180,827 |
| Loss on valuation of warrant liability | — | 192,914 |
| Interest expense in connection with the grant of warrants | — | 335,273 |
| Changes in assets and liabilities: | | |
| Notes receivable | (536,856) | (1,628) |
| Accounts receivable | (26,465) | (20,032) |
| Prepaid expenses and other | 25,780 | 20,080 |
| Accounts payable | 193,647 | 211,535 |
| Accrued expenses | 89,536 | 103,763 |
| Deferred revenues | (38,726) | 48,425 |
| Total adjustments | 3,949,943 | 3,289,449 |
| Net cash used in operating activities | (3,309,989) | (2,270,394) |
| Cash flows from investing activities: | | |
| Purchase of property and equipment | (5,209) | (71,728) |
| Net cash used in investing activities | (5,209) | (71,728) |
| Cash flows from financing activities: | | |
| Proceeds from convertible notes payable | 250,000 | — |
| Proceeds from loans payable | 250,000 | 360,000 |
| Placement fees in connection with notes payable | — | (23,434) |
| Repayment of convertible notes payable | (250,000) | — |
| Repayment of notes payable | (194,698) | (25,000) |
| Repayment of loan payable | (2,916) | (21,486) |
| Proceeds from sale of Mandatory Redeemable Series B preferred stock | 2,000,000 | — |
| Proceeds from sale of Series A preferred stock | — | 1,700,000 |
| Placement fees and other expenses paid | (112,918) | (273,609) |
| Net cash provided by financing activities | 1,939,468 | 1,716,471 |
| Net decrease in cash | (1,375,730) | (625,651) |
| Cash - beginning of period | 3,146,841 | 766,464 |
| Cash - end of period | \$ 1,771,111 | \$ 140,813 |
| Supplemental disclosure of cash flow information: | | |
| Cash paid for: | | |
| Interest | \$ 247,078 | \$ 9,253 |
| Non-cash investing and financing activities: | | |
| Common stock issued for debt and accrued interest | \$ — | \$ 46,250 |

The accompanying notes should be read in conjunction with the unaudited consolidated financial statements

5

MDWERKS, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007

NOTE 1 — ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization

On November 16, 2005, a wholly-owned subsidiary of MDwerks, Inc. (f/k/a Western Exploration, Inc., and hereinafter referred to as the “Company”) was merged with and into MDwerks Global Holdings, Inc., a Florida corporation (“MDwerks”), with MDwerks surviving. The Company acquired all of the outstanding capital stock of MDwerks in exchange for issuing 9,246,339 shares of the Company’s common stock, par value \$0.001 per share to MDwerks’ stockholders, which at closing of the Merger Agreement represented approximately 87.4% of the issued and outstanding shares of the Company’s common stock. In connection with the Merger, the Company changed its corporate name to MDwerks, Inc.

The Company has four operating subsidiaries. Xen Medical Systems, Inc. ("Xeni Medical") was incorporated under the laws of the state of Delaware on July 21, 2004. Xen Medical provides a Web-based package of electronic claims solutions to the healthcare provider industry through Internet access to it’s “MDwerks” suite of proprietary products and services so that healthcare providers can significantly improve daily insurance claims transaction processing, administration and management. Xen Financial Services, Corp. ("Xeni Financial") was incorporated under the laws of the state of Florida on February 3, 2005. Xen Financial offers financing and advances to health care providers secured by claims processed through the MDwerks system. Xen Medical Billing, Corp. ("Xeni Billing") was incorporated under the laws of the state of Florida on March 2, 2005. Xen Billing offers health care providers billing services facilitated through the MDwerks system. Patient Payment Solutions, Inc. (“PPS”) was incorporated under the laws of the state of Florida on May 30, 2007. PPS will offer healthcare providers a payment improvement process for “out of network” claims.

Going concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has suffered losses that raise substantial doubt about its ability to continue as a going concern. While the Company is attempting to attain revenue growth and profitability, the growth has not been significant enough to support the Company’s daily operations. Management intends to attempt to raise additional funds by way of a public or private offering and make strategic acquisitions. While the Company believes in the viability of its strategy to improve sales volume and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent on the Company’s ability to further implement its business plan and generate revenue. The Company believes it is taking actions to further implement its business plan and generate revenue, including the institutional financing described in Note 4 and additional private placement or debt financing transactions, which the Company is currently pursuing, but the Company will not be able to continue as a going concern in the absence of obtaining sufficient funding. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

As reflected in the accompanying consolidated financial statements, the Company has stockholders’ deficiency of \$962,602 and a working capital deficiency of \$1,161,786 at September 30, 2007.

Basis of presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-QSB and Item 310(b) of Regulation S-B. Accordingly, the financial statements do not include all of the information and footnotes

Edgar Filing: MDwerks, Inc. - Form 10QSB

required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and such adjustments are of a normal recurring nature. These consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2006 and notes thereto and other pertinent information contained in the Form 10-KSB of the Company as filed with the Securities and Exchange Commission (the "Commission"). The results of operations for the nine months ended September 30, 2007 are not necessarily indicative of what the results will be for the full fiscal year ending December 31, 2007.

Certain amounts previously reported for in 2006 have been reclassified to conform with the classifications used in 2007. Such reclassifications have no effect on the reported net loss.

MDWERKS, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007

NOTE 1 — ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Use of estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

Fair value of financial instruments

Statement of Financial Accounting Standards No. 107, "Disclosures about Fair Value of Financial Instruments," requires disclosures of information about the fair value of certain financial instruments for which it is practicable to estimate the value. For purpose of this disclosure, the fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation.

The carrying amounts reported in the consolidated balance sheet for cash, notes receivable, accounts receivable, accounts payable and accrued expenses, notes payable and loans payable approximate their fair market value based on the short-term maturity of these instruments.

Cash and cash equivalents

For purposes of the consolidated statements of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less and money market accounts to be cash equivalents.

At various times, the Company has deposits in excess of the Federal Deposit Insurance Corporation limit. The Company has not experienced any losses on these accounts.

Advertising

The Company expenses advertising costs as incurred. Advertising costs charged to operations were approximately \$93,593 and \$103,816 for the nine months ended September 30, 2007 and 2006, respectively.

Property and equipment

Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful life.

Revenue recognition

The Company follows the guidance of the Securities and Exchange Commission's ("SEC") Staff Accounting Bulletin 104 for revenue recognition. In general, the Company records revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. The following policies reflect specific criteria for the various revenue streams of the Company.

Revenue derived from fees related to claims and contract management services are generally recognized when services are provided to the customer.

MDWERKS, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007

NOTE 1 — ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Revenue recognition (continued)

The Company, through its subsidiaries, provides advance funding for medical claims and term loan services to unaffiliated healthcare providers that are customers of the Company. The customer advances are typically collateralized by Security Agreements granting first position liens on the medical claims submitted by its customers to third party payors (the “Payors”). The advances are repaid through the remittance of payments of customer medical claims, by Payors, directly to the Company. The Company can withhold from these advances interest, an administrative fee and other charges as well as any amount for prior advances that remain unpaid after a specified number of days. These interest charges, administrative fees and other charges are recognized as revenue when earned. There is no right of cancellation or refund provisions in these arrangements and the Company has no further obligations once the services are rendered.

Revenue derived from fees related to billing and collection services are generally recognized when the customer’s accounts receivable are collected.

Revenue from implementation fees are generally recognized over the term of the customer’s agreement. Revenue derived from maintenance, administrative and support fees are generally recognized at the time the services are provided to the customer.

Income taxes

Income taxes are accounted for under the asset and liability method of Statement of Financial Accounting Standards No. 109, “Accounting for Income Taxes” (“SFAS 109”). Under SFAS 109, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under SFAS 109, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Loss per common share

Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing net income by the weighted average number of shares of common stock, potential common stock and potentially dilutive securities outstanding during each period. As of September 30, 2007, the Company had outstanding options to purchase an aggregate of 3,031,250 shares of common stock and warrants to purchase an aggregate of 5,566,345 shares of Common Stock, which could potentially dilute future earnings per share. Diluted loss per common share has not been presented for the nine months ended September 30, 2007 since the impact of the stock options and warrants would be antidilutive. As of September 30, 2006, the Company had outstanding options to purchase an aggregate of 1,726,250 shares of common stock, warrants to purchase an aggregate of 1,439,085 shares of common stock, and 566,667 shares of common stock issuable upon conversion of preferred stock which could potentially dilute future earnings per share.

MDWERKS, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007

NOTE 1 — ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Stock-based compensation

The Company adopted Statement of Financial Accounting Standards No. 123 (revised 2004), *Share Based Payment* (“SFAS No. 123R”) utilizing the modified prospective method. SFAS No. 123R establishes the financial accounting and reporting standards for stock-based compensation plans. As required by SFAS No. 123R, the Company recognizes the cost resulting from all stock-based payment transactions including shares issued under its stock option plans in the consolidated financial statements.

Recent accounting pronouncements

In February 2006, the Financial Accounting Standards Board issued Statement No. 155 (“SFAS No 155”), “Accounting for Certain Hybrid Instruments: An Amendment of FASB Statements No. 133 and 140”. Management does not believe that this statement will have a significant impact as the Company does not use such instruments.

In July 2006, the Financial Accounting Standards Board (“FASB”) issued FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes, an interpretation of FASB Statement No. 109” (“FIN 48”), which provides criteria for the recognition, measurement, presentation and disclosure of uncertain tax positions. A tax benefit from an uncertain position may be recognized only if it is “more likely than not” that the position is sustainable based on its technical merits. The provisions of FIN 48 are effective for fiscal years beginning after December 15, 2006. The Company does not expect FIN 48 will have a material effect on its consolidated financial condition or results of operations.

In September 2006, the SEC issued Staff Accounting Bulletin (“SAB”) 108 which provides interpretive guidance on how the effects of the carryover or reversal of prior year misstatements should be considered in quantifying a current year misstatement. SAB 108 is effective for the first interim period following the first fiscal year ending after November 15, 2006, which, for us, is effective for fiscal 2007 beginning January 1, 2007. We believe that the adoption of SAB 108 will not have a material impact on the Company’s results of operations, cash flows or financial condition.

In September 2006, the FASB issued Statement of Financial Accounting Standards No. 157 (“SFAS 157”), Fair Value Measurements. SFAS 157 provides guidance for measuring the fair value of assets and liabilities. It requires additional disclosures related to the extent to which companies measure assets and liabilities at fair value, the information used to measure fair value, and the effect of fair value measurements on earnings. SFAS 157 is effective for fiscal years beginning after November 15, 2007. The Company is in the process of determining what effect, if any, the adoption of SFAS 157 will have on its consolidated results of operations and financial condition.

MDWERKS, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007

NOTE 1 — ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

In February 2007, the FASB issued SFAS No. 159 *The Fair Value Option for Financial Assets and Financial Liabilities - including an Amendment of SFAS No. 115*, (“SFAS 159”), which permits an entity to measure many financial assets and financial liabilities at fair value that are not currently required to be measured at fair value. Entities that elect the fair value option will report unrealized gains and losses in earnings at each subsequent reporting date. The fair value option may be elected on an instrument-by-instrument basis, with few exceptions. SFAS 159 amends previous guidance to extend the use of the fair value option to available-for-sale and held-to-maturity securities. The Statement also establishes presentation and disclosure requirements to help financial statement users understand the effect of the election. SFAS No. 159 is effective as of the beginning of the first fiscal year beginning after November 15, 2007. The Company is currently evaluating the impact of adopting SFAS 159.

On July 25, 2007, the Securities and Exchange Commission unanimously approved the Public Company Accounting Oversight Board's (PCAOB) proposed Auditing Standard No. 5, *An Audit of Internal Control Over Financial Reporting That is Integrated With An Audit of Financial Statement*. Auditing Standard No. 5 provides the new professional standards and related performance guidance for independent auditors to attest to, and report on, management's assessment of the effectiveness of internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002 (SOX). We have engaged a qualified third-party to assist us with the preparations for management's assessment of the effectiveness of internal controls over financial reporting required by the end of this fiscal year and with the documentation and procedures required for our external auditor attestation requirement, which becomes effective fiscal year ending 2008.

The Company does not believe that any other recently issued, but not yet effective accounting standards will have a material effect on the Company's consolidated financial position, results of operations or cash flows.

NOTE 2 — ACCOUNTS AND NOTES RECEIVABLE

Accounts and notes receivable are reported at their outstanding unpaid principal balances reduced by an allowance for doubtful accounts. The Company estimates doubtful accounts based on historical bad debts, factors related to specific customers' ability to pay and current economic trends. The Company writes off receivables against the allowance when a balance is determined to be uncollectible. At September 30, 2007, the Company has no allowance for doubtful accounts.

Accounts receivable are recorded when revenue has been recognized but not yet collected. At September 30, 2007, the Company had \$82,056 of accounts receivable from implementation, processing, collection, and other fees, and disbursements not yet collected.

At September 30, 2007, the Company advanced funds to healthcare providers under lines of credit and note agreements, respectively, aggregating \$1,010,549. Advances under the lines of credit are due to be repaid out of collections from insurance claims and other receivables. The Company charged the healthcare providers interest and other charges as defined in the agreements.

NOTE 3 — PROPERTY AND EQUIPMENT

At September 30, 2007, property and equipment consisted of the following:

Estimated Life

Edgar Filing: MDwerks, Inc. - Form 10QSB

| | | | |
|---------------------------------|-----------|----|----------|
| Office furniture and equipment | 5-7 Years | \$ | 27,077 |
| Computer equipment and software | 3-5 Years | | 181,820 |
| Total | | | 208,897 |
| Less: accumulated depreciation | | | (81,724) |
| Property and equipment, net | | \$ | 127,173 |

10

MDWERKS, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007

NOTE 4 — NOTES PAYABLE

On August 24, 2006, we received gross proceeds of \$250,000 (net proceeds of \$236,566, after expenses) in connection with a financing provided by an unrelated party. In connection with the financing, we issued a secured promissory note in the original principal amount of \$250,000 (the "Note") and a three year warrant to purchase 111,111 shares of the Company's common stock at a price of \$2.25 per share. The Note bears interest at the rate of 7% per year, payable monthly in arrears and was to become due and payable on August 24, 2007. In connection with an extension on repayment of this secured promissory note from August 24, 2007 to October 1, 2007, the Company granted options to purchase 75,000 shares of its common stock at an exercise price of \$0.67 per share which options expire on September 27, 2017. The fair market value of each stock option was estimated on the date of grant using the Black-Scholes option-pricing model in accordance with SFAS No. 123R using the following weighted-average assumptions: expected dividend yield 0%; risk-free interest rate of 4.23%; volatility of 116% and an expected term of 10 years. These options, valued at \$51,000, were recorded as deferred compensation and will be expensed monthly until September 2010.

At September 30, 2007, principal payments made under the mandatory prepayment provisions had reduced the Note balance to \$153,664. On October 1, 2007 the Company paid the remaining unpaid principal of the \$250,000 August 24, 2006 notes payable, together with all accrued interest, to the unrelated party.

On August 24, 2006, the Company received gross proceeds of \$110,000 (net proceeds of \$100,000, after expenses) in connection with a financing provided equally by two unrelated parties. These notes bear interest at 10% per year, and both interest and principal were due on January 21, 2007. In connection with the financing, the Company issued 10,000 shares of its common stock at a fair market value on the date of grant of \$39,800 or \$3.98 per share which was recorded as a discount on notes payable to be amortized over the term of the Notes. For the nine months ended September 30, 2007, amortization of this debt discount amounted to \$7,960 and is included in interest expense. In addition, the Company paid a total cash fee of \$23,434 in connection with the above promissory notes for placement agent fees and related expenses. Accordingly, these fees were treated as deferred issuance cost to be amortized over their respective note terms. For the nine months ended September 30, 2007, amortization of deferred issuance cost amounted to \$10,954. On January 21, 2007 the Company paid the August 24, 2006 notes payable of \$110,000, together with all accrued interest, to the two unrelated parties.

On each of October 20, 2006 and November 9, 2006 the Company received gross proceeds of \$2,500,000 (\$2,375,000 net proceeds) or \$5,000,000 (\$4,750,000 net proceeds) in the aggregate in connection with a financing provided by Gottbetter Capital Master, Ltd., an unaffiliated accredited institutional investor ("Gottbetter").

In connection with an extension until February 1, 2008 of repayment of principal on the Senior Notes described above, the Company granted to Gottbetter an additional five year Series D warrants to purchase 500,000 shares of its common stock at an exercise price of \$0.68 per share which warrants expire on September 27, 2012. These warrants were treated as a discount on the secured promissory note and were valued at \$252,361 to be amortized over the 4-month extension. The fair market value of each stock option was estimated on the date of grant using the Black-Scholes option-pricing model in accordance with SFAS No. 123R using the following weighted-average assumptions: expected dividend yield 0%; risk-free interest rate of 4.23%; volatility of 116% and an expected term of 5 years.

MDWERKS, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007

NOTE 4 — NOTES PAYABLE (continued)

For the nine months September 30, 2007, amortization of the debt discount amounted to \$1,208,594.

The promissory notes are as follows at September 30, 2007:

| | |
|---------------------------------------------------------------------|--------------|
| Notes payable | \$ 5,153,665 |
| Less: unamortized discount on notes payable | (3,075,587) |
| Notes payable, net | \$ 2,078,078 |
| Less current portion | (1,686,269) |
| Notes payable, net of discount of \$2,829,252, less current portion | \$ 391,809 |

On August 31, 2007 we received gross proceeds of \$250,000 in connection with a financing provided by Vicis Capital Master Fund, an unaffiliated accredited investor. In connection with the financing, we issued a 31-day Convertible Note to Vicis in the original principal amount of \$250,000.

On September 28, 2007 we received gross proceeds of \$2,000,000 (net proceeds of \$1,691,445 after repayment of the \$250,000 31-day August 31, 2007 Convertible Note, interest and closing expenses) in connection with a financing provided by Vicis Capital Master Fund, an unaffiliated accredited institutional investor (the "Investor"). In connection with the financing, pursuant to the terms of a Securities Purchase Agreement, we issued 200 shares of Series B Convertible Preferred Stock (a "Series B Preferred Stock"), a seven year Series F Warrant to purchase 1,500,000 shares of our common stock at a price of \$2.25 per share and a seven year Series G Warrant to purchase 1,000,000 shares of our common stock at a price of \$2.50 per share. As security for our obligations, we, along with our subsidiaries, MDwerks, Xen Medical, Xen Financial, Xen Billing and PPS entered into Security Agreements with the Investor, pursuant to which we granted a security interest in all of our assets, except for the accounts receivable and certain contract rights of Xen Financial Services, Corp., to the Investor.

Our subsidiaries, MDwerks, Xen Medical, Xen Financial, Xen Billing and PPS are also parties to Guaranty Agreements, pursuant to which they have agreed to unconditionally guaranty our obligations under the Series B Preferred Stock and the documents entered into by us in connection the sale of the Series B Preferred Stock.

MDWERKS, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007

NOTE 4 — NOTES PAYABLE (continued)

In connection with the sale of the Series B Preferred Stock, we entered into a Registration Rights Agreement, pursuant to which we agreed to register for resale, the shares of our common stock into which the Series B Preferred Stock is convertible and the shares of our common stock for which the Series F Warrants and the Series G Warrants are exercisable.

In connection with the Sale of the Series B Preferred Stock the Company entered into an Amendment, Consent and Waiver agreement with Gottbetter Capital Master, Ltd. (the "Consent and Waiver Agreement").

The following summary description of the material agreements entered into in connection with the transaction described above.

Securities Purchase Agreement

The Securities Purchase Agreement provides for the sale of (i) 200 shares of Series B Preferred Stock (ii) Series F Warrants to purchase an aggregate of 1,500,000 shares of Common Stock and (iii) Series G Warrants to purchase an aggregate of 1,000,000 shares of Common Stock. Pursuant to the Securities Purchase Agreement, the aggregate purchase price for the Series Preferred Stock, the Series F Warrants and the Series G Warrants was \$2 million. Payment was made by 1,691,445 in cash, the conversion of \$251,555 in principal and interest of the 31-day Convertible Note, dated August 31, 2007, issued by the Company to the Purchaser in the original principal amount of \$250,000 and deduction of certain closing expenses.

The Securities Purchase Agreement provides to the Investor, for a period of eighteen months after the closing date, a right of first refusal with respect to subsequent placements of equity or equity equivalent securities by us.

The Securities Purchase Agreement contains certain restrictions on our ability to: (i) declare dividends; (ii) reclassify, combine or reverse split our Common Stock; (iii) incur liens; (iii) incur certain types of indebtedness; (iv) issue classes of securities senior to, or *pari passu* with, the Series B Preferred Stock; (v) liquidate or sell a substantial portion of our assets; (vi) enter into transactions that would result in a Change of Control (as defined in the Securities Purchase Agreement); (vi) amend our charter documents in a way that adversely affects the rights of the Investor; (vii) except through Xen Financial, make loans to, or advances or guarantee the obligations of, third parties; (viii) make intercompany transfers; (ix) engage in transactions with officers, directors, employees or affiliates; (x) divert business to other business entities; (xi) make investments in securities or evidences of indebtedness (excluding of loans made by Xen Financial) in excess of \$250,000 in a calendar year; and (xii) file registration statements.

Events of default under the Securities Purchase Agreement include: (i) default in the payment of dividends on or the failure to redeem the Series B Preferred Stock when due; (ii) failure to perform the covenants contained in the Securities Purchase Agreement or the related transaction documents; (iii) failure to file, or cause to become effective, a registration statement covering the shares of Common Stock underlying the Series F Warrants, the Series G Warrants and the Series B Preferred Stock within the timeframes required by the Registration Rights Agreement or the failure to keep such registration effective as required by the Registration Rights Agreement; (iv) suspension from listing on the OTC Bulletin Board or other exchange for 10 consecutive trading days; (v) the failure to timely deliver shares of Common Stock upon conversion of the Series B Preferred Stock or exercise of the Series F Warrants or the Series G Warrants; (vi) default in the payment of indebtedness in excess of \$250,000; (vii) a judgment entered against us in excess of \$250,000; and (viii) insolvency, bankruptcy and similar circumstances.

The Securities Purchase Agreement also contains customary representations, warranties, covenants and indemnification provisions for transactions of the type entered into between the Company and Investor.

MDWERKS, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007

NOTE 4 — NOTES PAYABLE (continued)

Series B Preferred Stock

The Certificate of Designations, which designates the rights, preferences, privileges and terms of the Series B Preferred Stock (the “Certificate of Designations”) provides that the Series B Preferred Stock will rank senior to other classes of Common Stock and preferred stock that are currently outstanding as to distributions of assets upon liquidation, dissolution or winding up and as to payment of dividends on shares of equity securities.

Each share of Series B Preferred Stock is entitled to cumulative dividends at the annual rate of 8% of the stated value of the Series B Preferred Stock. The stated value of each share of Series B Preferred Stock is \$10,000. Dividends are payable in cash or additional shares of Series B Preferred Stock.

Each share of Series B Preferred Stock is convertible, at any time, at the option of the holder, into the number of shares of Common Stock determined by dividing the stated value of the Series B Preferred Stock by the conversion price. The initial conversion price of the Series B Preferred Stock is \$2.25 per share.

The conversion price is subject to adjustment for stock splits, dividends, subdivisions, distributions, reorganizations and similar transactions. Furthermore, the conversion price is also subject to adjustment in the event of the issuance of securities for a price below the conversion price then in effect or the issuance of convertible securities with an exercise or conversion price that is less than the then current conversion price for the shares of Series B Preferred Stock.

To the extent that any shares of Series B Preferred Stock remain outstanding on September 28, 2008, each holder thereof shall have the option to either require us to redeem such holder’s shares of Series B Preferred Stock or convert such holder’s shares of Series B Preferred Stock into shares of Common Stock at the conversion price then in effect.

The Series B Preferred Stock also provides the holders thereof with the option to require us to redeem shares of Series B Preferred Stock in the event of a Change of Control (as defined in the Certificate of Designations).

The Series B Preferred Stock will vote on matters submitted to our stockholders as if the Series B Preferred Stock had been converted into shares of Common Stock pursuant to the terms of the Certificate of Designations. To the extent the holders of Series B Preferred Stock are required to vote separately, as a class, the affirmative vote of the holders of a majority of the outstanding shares of Series B Preferred Stock will be required to approve the matter to be voted upon.

Series F Warrants

The Series F Warrants are exercisable at a price of \$2.25 per share for a period of seven years from the date of issuance. The Series F Warrants may be exercised on a cashless basis. The exercise price will be subject to adjustment in the event of subdivision or combination of shares of our common stock and similar transactions, distributions of assets, issuances of shares of common stock with a purchase price below the exercise price of the Series F Warrants, issuances of any rights, warrants or options to purchase shares of our common stock with an exercise price below the exercise price of the Series F Warrants, issuances of convertible securities with a conversion price below the exercise price of the Series F Warrants.

Series G Warrants

The Series G Warrants are exercisable at a price of \$2.50 per share for a period of seven years from the date of issuance. The Series G Warrants may be exercised on a cashless basis. The exercise price will be subject to adjustment in the event of subdivision or combination of shares of our common stock and similar transactions, distributions of assets, issuances of shares of common stock with a purchase price below the exercise price of the Series G Warrants, issuances of any rights, warrants or options to purchase shares of our common stock with an exercise price below the exercise price of the Series G Warrants, issuances of convertible securities with a conversion price below the exercise price of the Series G Warrants.

MDWERKS, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007

NOTE 4 — NOTES PAYABLE (continued)

Security Agreement

We, along with our subsidiaries MDwerks, Xeni Medical, Xeni Financial, Xeni Billing, and PPS entered into Security Agreements with the Investor. The Security Agreements provide for liens in favor of the Investor on all of our assets, including the assets of each of our subsidiaries, except for the accounts receivable and certain contract rights of Xeni Financial Services, Corp.

Guaranty Agreement

Our subsidiaries, MDwerks, Xeni Medical, Xeni Financial, Xeni Billing, and PPS entered into Guaranty Agreements with the Investor, pursuant to which they have agreed to unconditionally guaranty our obligations under the Series B Preferred Stock and the documents entered into by us in connection with the sale of the Series B Preferred Stock.

Registration Rights Agreement

We entered into a Registration Rights Agreement with the Investor. The Registration Rights Agreement requires us to file a registration statement covering the resale of the shares underlying the Series B Preferred Stock, the Series F Warrants and the Series G Warrants within 365 calendar days after the closing date. We are required to cause such registration statement to become effective on or before the date which is 485 calendar days after the filing of such registration statement. In addition to it being an event of default under the Securities Purchase Agreement, if we fail to file such registration statement in the time frame required, fail to cause it to become effective in the time frame required, or fail to maintain the effectiveness of the registration statement as required by the Registration Rights Agreement, we will be required to pay a cash penalty in the amount of 2% of the aggregate stated value of the Series B Preferred Stock for each month, or part thereof, that the registration statement is not filed or effective, as the case may be. The cash penalty is limited to 15% of the aggregate stated value of the Series B Preferred Stock.

The Registration Rights Agreement also provides for piggyback registration rights.

Amendment, Consent & Waiver Agreement

In connection with the transactions described above, we entered into the Consent and Waiver Agreement with Gottbetter Capital Master, Ltd. (“Gottbetter”), whereby, among other things: (i) Gottbetter consented to the transactions described above, (ii) Gottbetter agreed to delay, until February 1, 2008, principal payments under the Senior Secured Convertible Note issued by the Corporation to Gottbetter on October 19, 2006 (the “October Note”) and under the Senior Secured Convertible Note issued by the Corporation to Gottbetter on November 9, 2006 (the “November Note”), (iii) Gottbetter agreed that its right of first refusal with respect to subsequent financings will be on a *pro rata, pari passu* basis with Vicis and (v) Gottbetter released its security interest in certain collateral of Xeni Financial.

MDWERKS, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007

NOTE 4 — NOTES PAYABLE (continued)

Series D Warrant

In consideration of Gottbetter entering into the Consent and Waiver Agreement, we issued to Gottbetter a Series D Warrant to purchase 500,000 shares of our Common Stock. The Series D Warrant is exercisable at a price of \$2.25 per share for a period of five years from the date of issuance. The Series D Warrant may be exercised on a cashless basis. The exercise price will be subject to adjustment in the event of subdivision or combination of shares of our common stock and similar transactions, distributions of assets, issuances of shares of common stock with a purchase price below the exercise price of the Series D Warrant, issuances of any rights, warrants or options to purchase shares of our common stock with an exercise price below the exercise price of the Series D Warrant, issuances of convertible securities with a conversion price below the exercise price of the Series D Warrant.

Amended & Restated Notes

In order to memorialize the extension of the principal payment date to February 1, 2008 in the October Note and the November Note, we issued to Gottbetter an amended and restated October Note and an amended and restated November Note.

In accordance with SFAS No. 133 and Emerging Issues Task Force Issue 00-19 (“EITF 00-19”), “Accounting for Derivative Financial Instruments Indexed To, and Potentially Settled in, a Company's Own Stock”, the Company is required to record the fair value of the embedded beneficial conversion feature (ECF) and warrants as a liability since the Company has to use its “best efforts” to file a registration statement and maintain its effectiveness for a period of two years from the effective date. In connection with the initial sales of the Series A Preferred Stock, the initial estimated fair values allocated to the ECF were \$913,777 which was recorded as a deemed dividend. The initial fair value allocated to the warrants of \$768,751 was allocated to warrant liability. For the nine months ended September 30, 2006, the Company revalued these warrants resulting in a loss on valuation of warrant liability of \$192,914.

NOTE 5 — LOAN PAYABLE

The Company has a loan payable to an unrelated individual in the amount of \$69,559. The loan bears interest at 8% per annum and is payable on a monthly basis. The loan shall be repaid proportionally upon repayment of certain of the Company's notes receivable.

The Company also has a loan payable to a customer of the Company in the amount of \$250,000. This customer has provided this non-interest bearing loan to assist with interim financing and to fund equipment purchases incurred on behalf of the customer. During October 2007, \$210,000 of this loan payable has been repaid to the customer.

MDWERKS, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007

NOTE 6 — STOCKHOLDERS' DEFICIENCY**Common stock**

The Company is authorized to issue 100,000,000 shares of Common stock, \$.001 par value, with such designations, rights and preferences as may be determined from time to time by the Board of Directors. As of September 30, 2007, there are 12,940,065 shares issued and outstanding.

During August, 2007, two shareholders converted a total of three shares of the Company's Series A convertible preferred stock into 60,000 shares of common stock.

Preferred stock

The Company is authorized to issue 10,000,000 shares of preferred stock, \$.001 par value, with such designations, rights and preferences as may be determined from time to time by the Board of Directors. As of September 30, 2007, there are no preferred stock shares issued and outstanding.

The Company is authorized to issue 1,000 shares of Series A Convertible Preferred stock, \$0.001 par value with such designations, rights and preferences as may be determined from time to time by the Board of Directors. Between February 1, 2006 and September 30, 2006, the Company sold 28.3 Units to accredited investors. Each unit consists of one share of our Series A Convertible Preferred Stock, par value \$.001 per share, and a detachable, transferable Series A Warrant to purchase 20,000 shares of our common stock, at a purchase price of \$3.00 per share. Between August 11, 2006 and September 30, 2007, 26.3 shares of Series A Convertible Preferred Stock were converted into 526,667 shares of common stock leaving 2 Series A Convertible Preferred Stock outstanding as of September 30, 2007.

The Company is authorized to issue 250 shares of Series B Convertible Preferred stock, \$0.001 par value with such designations, rights and preferences as may be determined from time to time by the Board of Directors. On September 28, 2007, 200 shares of Series B preferred stock were issued in connection with the Securities Purchase Agreement. As of September 30, 2007, there are 200 Series B Convertible Preferred Stock shares issued and outstanding.

Common stock options

A summary of the status of the Company's outstanding stock options as of September 30, 2007 and changes during the period ending on that date is as follows:

| | Shares | Weighted Average Exercise Price | Aggregate Intrinsic Value |
|------------------------------------------------------------------|-----------|---------------------------------------|------------------------------|
| Outstanding at December 31, 2006 | 2,876,250 | \$ 3.04 | |
| Granted | 175,000 | 0.67 | |
| Exercised | — | — | |
| Forfeited | (20,000) | \$ 1.39 | |
| Outstanding at September 30, 2007 | 3,031,250 | \$ 2.91 | \$ 0 |
| Options exercisable at end of period | 1,377,082 | \$ 2.74 | |
| Weighted-average fair value of options granted during the period | \$ 0.67 | | |

MDWERKS, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007

NOTE 6 — STOCKHOLDERS' DEFICIENCY**Common stock options (continued)**

The following information applies to options outstanding at September 30, 2007:

| Range of Exercise Prices | Options Outstanding | | | Options Exercisable | |
|--------------------------|---------------------|-----------------------------------------------------------------|------------------------------------------|---------------------|------------------------------------------|
| | Shares | Weighted Average Remaining Contractual Life (Years) | Weighted Average Exercise Price | Shares | Weighted Average Exercise Price |
| \$0.67 | 175,000 | 10.00 | \$ 0.67 | 33,333 | \$ 0.67 |
| \$1.39 | 105,000 | 9.25 | \$ 1.39 | 85,000 | \$ 1.39 |
| \$2.25 | 1,025,000 | 9.00 | \$ 2.25 | 683,333 | \$ 2.25 |
| \$3.25 | 190,000 | 8.25 | \$ 3.25 | 63,333 | \$ 3.25 |
| \$3.40 | 860,000 | 8.25 | \$ 3.40 | 286,667 | \$ 3.40 |
| \$4.00 - 4.25 | 676,250 | 8.75 | \$ 4.03 | 225,416 | \$ 4.03 |
| | 3,031,250 | | \$ 2.91 | 1,377,082 | \$ 2.74 |

In connection with previously granted stock options, the Company recognized stock-based compensation expense of \$2,506,281 for the nine months ended September 30, 2007 and \$1,878,572 for the nine months ended September 30, 2006.

As of September 30, 2007, the total future compensation expense related to non-vested options not yet recognized in the consolidated statement of operations is approximately \$1,787,604, which will be recognized through September 2010.

Common stock warrants

A summary of the status of the Company's outstanding stock warrants granted as of December 31, 2006 and changes during the period is as follows:

| | Shares | Weighted Average Exercise Price |
|-------------------------------------------------|-----------|---------------------------------------|
| Outstanding at December 31, 2006 | 2,566,345 | \$ 2.67 |
| Granted | 3,000,000 | 2.33 |
| Exercised | — | — |
| Forfeited | — | — |
| Outstanding at September 30, 2007 | 5,566,345 | \$ 2.49 |
| Common stock issuable upon exercise of warrants | 5,566,345 | \$ 2.49 |

MDWERKS, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007

NOTE 6 — STOCKHOLDERS' DEFICIENCY**Common stock warrants (continued)**

| Range of Exercise Price | Common Stock issuable upon exercise of warrants outstanding | | | Common Stock issuable upon Warrants Exercisable | | |
|-------------------------|-------------------------------------------------------------|-----------------------------------------------------|---------------------------------|-------------------------------------------------|---------------------------------|--|
| | Number Outstanding at September 30, 2007 | Weighted Average Remaining Contractual Life (Years) | Weighted Average Exercise Price | Number Exercisable at September 30, 2007 | Weighted Average Exercise Price | |
| \$1.25 | 199,000 | 2.88 | \$ 1.25 | 199,000 | \$ 1.25 | |
| \$1.50 | 56,667 | 3.74 | \$ 1.50 | 56,667 | \$ 1.50 | |
| \$2.25 | 2,486,111 | 5.93 | \$ 2.25 | 2,486,111 | \$ 2.25 | |
| \$2.50 | 1,640,400 | 4.71 | \$ 2.50 | 1,640,400 | \$ 2.50 | |
| \$3.00 | 579,167 | 1.62 | \$ 3.00 | 579,167 | \$ 3.00 | |
| \$3.25 | 375,000 | 4.05 | \$ 3.25 | 375,000 | \$ 3.25 | |
| \$3.76 | 225,000 | 2.05 | \$ 3.76 | 225,000 | \$ 3.76 | |
| \$4.00 | 5,000 | 2.05 | \$ 4.00 | 5,000 | \$ 4.00 | |
| | 5,566,345 | | \$ 2.49 | 5,566,345 | \$ 2.49 | |

Registration rights

The Company filed a “resale” registration statement with the SEC covering all shares of common stock and shares of common stock underlying the warrants (including shares of common stock and underlying warrants issued to the Placement Agent) issued in connection with the September 13, 2005 Private Placement. The Company agreed that it will maintain the effectiveness of the “resale” registration statement from the effective date through and until the earlier of two years and the time at which exempt sales pursuant to Rule 144(k) may be permitted. The Company agreed to use its best efforts to respond to any SEC comments to the “resale” registration statement on or prior to the date which is 20 business days from the date such comments were received, but in any event not later than 30 business days from the date such comments were received. The “resale” registration statement became effective on December 7, 2006.

In the event the “resale” registration statement had not been filed with the SEC on or prior to the date which is 180 days after the last closing date of the Private Placement, each investor in the Private Placement would have received as liquidating damages an additional number of shares of common stock equal to 2% of the total number of shares of common stock purchased by the investor in the Private Placement for each month (or portion thereof) that the Registration Statement was not filed, provided that the aggregate increase in such shares of common stock as a result of the delinquent filing would in no event exceed 20% of the original number of shares of common stock purchased in the Private Placement.

In the event that the Company had failed to respond to SEC comments to the Registration Statement within 30 business days, each investor in the Private Placement would have received an additional number of shares of common stock equal to 2% of the total number of shares of common stock purchased by the investor in the Private Placement for each month (or portion thereof) that a response to the comments to the Registration Statement has not been submitted to the SEC, provided that the aggregate increase in such shares shall in no event exceed 20% of the original

number of shares of common stock purchased in the Private Placement.

19

MDWERKS, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007

NOTE 6 — STOCKHOLDERS' DEFICIENCY

Registration rights (continued)

Pursuant to the February 1, 2006 Series A Convertible Preferred Private Placement Subscription documents, we agreed to file a registration statement with the Securities and Exchange Commission to register the shares and warrants held by the selling security holders for resale. That registration statement was declared effective on December 7, 2006. We have agreed to maintain the effectiveness of the registration statement from the effective date through and until the earlier of two years following December 31, 2005 (which was the termination date of the first private placement described above) or the earlier of two years following June 28, 2006 (which was the effective date of the termination of the second private placement described above) and such time as exempt sales pursuant to Rule 144(k) under the Securities Act of 1933 ("Rule 144(k)") may be permitted for purchasers of Units.

We also entered into a Registration Rights Agreement and amendment thereto with Gottbetter. The amended Registration Rights Agreement required us to file a registration statement covering the resale of 2,777,778 shares of common stock underlying the Senior Notes. The registration statement covering the resale of the shares of common stock underlying the Senior Notes became effective on December 7, 2006. In addition to it being an event of default under the Senior Notes, if we fail to maintain the effectiveness of the registration statement as required by the Registration Rights Agreement, the exercise price of the Series D and the Series E Warrants will immediately be reduced by \$0.25 per share and then reduced by an additional \$0.10 per share for each thirty day period thereafter that the registration statement is not filed or effective, as the case may be, up to a maximum reduction of \$0.65.

We also entered into a Registration Rights Agreement with the Investor. The Registration Rights Agreement requires us to file a registration statement covering the resale of the shares underlying the Series B Preferred Stock, the Series F Warrants and the Series G Warrants within 365 calendar days after the closing date. We are required to cause such registration statement to become effective on or before the date which is 485 calendar days after the filing of such registration statement. In addition to it being an event of default under the Securities Purchase Agreement, if we fail to file such registration statement in the time frame required, fail to cause it to become effective in the time frame required, or fail to maintain the effectiveness of the registration statement as required by the Registration Rights Agreement, we will be required to pay a cash penalty in the amount of 2% of the aggregate stated value of the Series B Preferred Stock for each month, or part thereof, that the registration statement is not filed or effective, as the case may be. The cash penalty is limited to 15% of the aggregate stated value of the Series B Preferred Stock.

The Registration Rights Agreement also provides for piggyback registration rights.

NOTE 7 — COMMITMENTS

Lease agreements

The Company sub-leases its facility, on a month-to-month basis, under a master lease expiring July 2008. Rent expense for the nine months ended September 30, 2007 was \$70,626.

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATIONS

Overview

We offer a comprehensive technology-based selection of electronic medical claims processing, funding and collection solutions to the healthcare provider industry through an Internet Web browser. Our services help doctors, hospital based practices, and other healthcare providers and their vendors to significantly improve daily insurance claims transaction administration and management.

Our Xeni Medical Systems, Inc. ("Xeni Medical") CLAIMwerks™ solutions can provide actual contract based, insurance company comparable screening and analysis of medical claims directly from a client's practice management system, so that deficiencies and errors can be corrected before they are submitted to insurance companies for electronic payment. Further, the matching, settlement and posting of private insurance company claims payments is electronically performed for clients, minimizing the bookkeeping and investigation necessary to determine payment status and collection actions.

Since the system has the capability of analyzing value and risk of claims payment, clients may also qualify for pre-approved revolving line of credit advances on claims processed by our Xeni Financial Services, Corp. ("Xeni Financial") FUNDwerks™ solution. FUNDwerks™ can electronically manage loans, loan repayments and the movement of funds through linked bank accounts administered by us for banks or finance companies; clients can receive electronic advance funding on claims they select within five business days on commercially favorable terms.

Additionally, clients may choose to complete the claims management cycle by subscribing to the Xeni Medical Billing, Inc. ("Xeni Billing") BILLwerks™ services, which can include patient billing and collections and/or managing third party appeals on the provider's behalf.

There is no major hardware or software investment required to use the Company's Web-based systems. All transactions are designed to comply with the Health Insurance Portability and Accountability Act of 1996 ("HIPAA").

On May 30, 2007, we formed a new subsidiary, Patient Payment Solutions, Inc. ("PPS"), to improve collections for health care providers that perform services "out-of-network". As of September 30, 2007, PPS has not begun to generate revenue and has incurred minimal expenses.

We offer our services to physician and clinical service group practices, hospitals, rehabilitation centers, nursing homes and certain related practice vendors by using internal and external resources. Internal resources consist mainly of specialized sales executives with industry knowledge and/or a portfolio of contacts. External resources consist primarily of independent sales representatives as well as channel associates, such as vendors of practice management systems and medical industry specific sales groups such as office management consultants. These sales resources can leverage an existing customer base and contacts. Our marketing is based on prioritizing potential subscribers by size, location and density, need for our products and services and distribution opportunities. Accordingly, we are focusing our initial marketing efforts in geographic areas such as California, Florida, Texas, New York and New Jersey. Each of these states contains a high concentration of prospective clients.

Because we have had a limited operating history, it is difficult to accurately forecast our revenues and expenses. Additionally, our operations will continue to be subject to risks inherent in the establishment of a new business, including, among other things, efficiently deploying our capital, developing our product and services offerings, developing and implementing our marketing campaigns and strategies and developing awareness and acceptance of our products. Our ability to generate future revenues will be dependent on a number of factors, many of which are beyond our control, including the pricing of other services, overall demand for our products, market competition and government regulation.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We apply the Securities and Exchange Commission's Staff Accounting Bulletin 104 for revenue recognition. In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. We have identified the policy below as critical to our business operations and understanding of our financial results:

Revenues derived from fees related to claims and contract management services are generally recognized when services are provided to the customer. We provide advance funding for medical claims and term loan services to unaffiliated healthcare providers. These arrangements typically require us to advance funds to these unaffiliated healthcare providers (our customers) in exchange for liens on the receivables related to invoices remitted to their clients for services performed. The advances are generally repaid through the remittance of payments of receivables by their payors directly to us. We may withhold from these advances interest, a fee charged in consideration of administration of advance funding and loans and other charges as well as the amount of receivables relating to prior advances that remain unpaid after a specified number of days. These interest charges, administrative fees and other charges are recognized as revenue when earned and are calculated on a daily basis.

Revenues derived from fees related to billing and collection services are generally recognized when the customer's accounts receivable are collected. Revenues from implementation fees are generally recognized over the term of the customer agreement. Revenues derived from maintenance, administrative and support fees are generally recognized at the time the services are provided to the customer.

Results of Operations

For the Nine Months Ended September 30, 2007 Versus the Nine Months Ended September 30, 2006

Revenue

For the nine months ended September 30, 2007, we recorded total revenue of \$403,233. Of this total, we recorded service fee revenue of \$356,540, or 88.4% and financing income of \$46,693 or 11.6%. For the nine months ended September 30, 2006, we recorded total revenue of \$298,850. Of this total, we recorded service fee revenue of \$262,292, or 87.8% and financing income of \$36,558 or 12.2%.

Operating Expenses

Our operating expenses significantly increased for the nine months ended September 30, 2007 from the nine months ended September 30, 2006 principally as a result of higher compensation and consulting expenses, offset by lower selling, general and administrative expenses.

For the nine months ended September 30, 2007, total operating expenses were \$6,196,794 as compared to \$5,287,920 for the nine months ended September 30, 2006, an increase of \$908,874 or 17.2%. Included in this increase for the

nine months ended September 30, 2007 is the following:

1. We recorded compensation expense of \$4,073,320 as compared to \$3,193,895 for the nine months ended September 30, 2006. This \$879,425 or 27.5% increase was attributable to the hiring of permanent sales, operations and executive staff and the recording of stock-based compensation expense under FAS 123R for previous period stock option grants. The increase in compensation expense related to the new and existing permanent employees was \$251,716, or 7.9%. The stock-based compensation expense for the nine months ended September 30, 2007 was \$2,506,281 as compared to \$1,878,572 for the nine months ended September 30, 2006, an increase of \$627,709, or 19.6%. We expect cash and stock-based compensation expense to increase as we hire additional administrative, sales and technical personnel and record the expense of both current and future stock option grants; and

2. Consulting expense amounted to \$562,798 as compared to \$399,126 for the nine months ended September 30, 2006, an increase of \$163,672, or 41.0%. For the nine months ended September 30, 2007 and 2006, we paid consultants for business advisory services, temporary information technology support and various other services; and
3. Professional fees amounted to \$299,901 as compared to \$277,906 for the nine months ended September 30, 2006, an increase of \$21,995, or 7.9%. This expense was attributable to accounting fees for the audit of our financial statements and SEC filings and legal fees related to SEC filings, the Series A and Series B Convertible Preferred Stock offerings, the Convertible Notes Payable and other corporate matters; and
4. Selling, general and administrative expenses were \$1,260,775 as compared to \$1,416,993 for the nine months ended September 30, 2006, a decrease of \$156,218, or 11.0%. This decrease was principally attributable to a loss of \$180,736 on settlement of notes payable related to the issuance of common shares for debt conversion that was recorded during the nine months ended September 30, 2006.

For the nine months ended September 30, 2007 and 2006, selling, general and administrative expenses consisted of the following:

| | 2007 | 2006 |
|-------------------------------------------|--------------|--------------|
| Sales commissions | \$ 64,422 | \$ 140,807 |
| Advertising and promotion | 93,593 | 103,816 |
| Employee benefits and payroll taxes | 316,502 | 276,960 |
| Other selling, general and administrative | 786,258 | 895,410 |
| | \$ 1,260,775 | \$ 1,416,993 |

Other Income (Expenses)

For the nine months ended September 30, 2007, interest income was \$60,201 as compared to \$5,671 for the nine months ended September 30, 2006, an increase of \$54,530. This increase was due to an increase in interest-bearing cash deposits.

For the nine months ended September 30, 2007, interest expense was \$1,526,737 as compared to \$380,039 for the nine months ended September 30, 2006, an increase of \$1,146,698. This increase was due to an increase in borrowings and amortization of debt discount and deferred fees in connection with our notes payable.

In accordance with Emerging Issues Task Force Issue 00-19 (“EITF 00-19”), “Accounting for Derivative Financial Instruments Indexed To, and Potentially Settled in, a Company's Own Stock”, we recorded a loss on the revaluation of warrant liability of \$192,914 related to the change in fair value of the warrants during nine months ended September 30, 2006.

Net Loss

As a result of these factors, we reported a net loss of \$7,259,932 for the nine months ended September 30, 2007 as compared to a net loss of \$5,559,843 for the nine months ended September 30, 2006.

Deemed Dividend arising from beneficial conversion on Preferred Stock and Other Charges

During the nine months ended September 30, 2006, we recorded a deemed dividend arising from a beneficial conversion feature of preferred stock of \$913,777 which relates to our Series A Convertible Preferred Stock. This non-cash item is related to the beneficial conversion features on our Series A Convertible Preferred Stock. In addition, for the nine months ended September 30, 2006, we issued 76,000 shares of the Company's common stock to certain shareholders pursuant to agreements to offset the effect of dilutive financings of Xen Medical, Xen Billing and Xen Financial. The shares issued were valued at the fair market value at the date of issuance of \$246,240 and were treated as an additional charge to the loss attributable to common shareholders.

Net Loss Attributable to Common Shareholders

We reported a net loss attributable to common shareholders of \$7,259,932 for the nine months ended September 30, 2007 as compared to net loss attributable to common shareholders of \$6,719,860 for the nine months ended September 30, 2006. This translates to an overall per share loss available to shareholders of (\$.57) for the nine months ended September 30, 2007 as compared to a per share loss of (\$.57) for nine months ended September 30, 2006.

For the Three Months Ended September 30, 2007 Versus the Three Months Ended September 30, 2006

Revenue

For the three months ended September 30, 2007, we recorded total revenue of \$136,573. Of this total, we recorded service fee revenue of \$119,820, or 87.7% and financing income of \$16,753 or 12.3%. For the three months ended September 30, 2006, we recorded total revenue of \$158,113. Of this total, we recorded service fee revenue of \$147,726, or 93.4% and financing income of \$10,387 or 6.6%.

Operating Expenses

Our operating expenses significantly decreased for the three months ended September 30, 2007 from the three months ended September 30, 2006 principally as a result of decreased compensation expense, professional fees and selling, general and administrative expenses.

For the three months ended September 30, 2007, total operating expenses were \$1,835,304 as compared to \$2,484,610 for the three months ended September 30, 2006, a decrease of \$649,306 or 26.1%. Included in this decrease for the three months ended September 30, 2007 compared to the three months ended September 30, 2006 is the following:

1. We recorded compensation expense of \$1,229,568 as compared to \$1,730,160 for the three months ended September 30, 2006. This \$500,592 or 28.9% decrease was principally attributable to the recording of lower stock-based compensation expense under FAS 123R in the amount of \$614,089, offset by \$113,497 in higher salaries for employees. The stock-based compensation expense for the three months ended September 30, 2007 was \$710,847 as compared to \$1,324,936 for the three months ended September 30, 2006. We expect cash and stock-based compensation expense to increase as we hire additional administrative, sales and technical personnel and record the expense of both current and future stock option grants; and
2. Consulting expense amounted to \$158,360 as compared to \$144,081 for the three months ended September 30, 2006, an increase of \$14,279, or 9.9%. For the three months ended September 30, 2007 and 2006, we paid consultants for business advisory services, temporary information technology support and various other services; and
3. Professional fees amounted to \$74,215 as compared to \$153,782 for the three months ended September 30, 2006, a decrease of \$79,567, or 51.7%. This expense reduction was principally attributable to lower accounting fees for the

audit of our financial statements and SEC filings and legal fees related to SEC filings and stock offerings for the three months ended September 30, 2007 versus the three months ended September 30, 2006.

4. Selling, general and administrative expenses were \$372,161 as compared to \$456,587 for the three months ended September 30, 2006, a decrease of \$84,426, or 18.5%.

For the three months ended September 30, 2007 and 2006, selling, general and administrative expenses consisted of the following:

| | 2007 | 2006 |
|-------------------------------------------|-------------------|-------------------|
| Sales commissions | \$ 18,440 | \$ 35,378 |
| Advertising and promotion | 21,435 | 23,783 |
| Employee benefits and payroll taxes | 99,889 | 97,993 |
| Other selling, general and administrative | 232,397 | 299,433 |
| | \$ 372,161 | \$ 456,587 |

Other Income (Expenses)

For the three months ended September 30, 2007, interest income was \$13,492 as compared to \$1,123 for the three months ended September 30, 2006, an increase of \$12,369. This increase was due to an increase in interest-bearing cash deposits.

For the three months ended September 30, 2007, interest expense was \$500,601 as compared to \$372,291 for the three months ended September 30, 2006, an increase of \$128,310. This increase was due to an increase in borrowings and amortization of debt discount and deferred fees in connection with our notes payable.

In accordance with Emerging Issues Task Force Issue 00-19 (“EITF 00-19”), “Accounting for Derivative Financial Instruments Indexed To, and Potentially Settled in, a Company’s Own Stock”, we recorded a loss on the revaluation of warrant liability of \$0 compared to a gain of \$1,030,338 related to the change in fair value of the warrants during three months ended September 30, 2006.

Net Loss

As a result of these factors, we reported a net loss of \$2,184,840 for the three months ended September 30, 2007 as compared to a net loss of \$1,670,829 for the three months ended September 30, 2006.

Net Loss Attributable to Common Shareholders

We reported a net loss attributable to common shareholders of \$2,184,840 for the three months ended September 30, 2007 as compared to net loss attributable to common shareholders of \$1,670,829 for the three months ended September 30, 2006. This translates to an overall per share loss available to shareholders of (\$.17) for the three months ended September 30, 2007 as compared to a per share loss of (\$.14) for three months ended September 30, 2006.

Liquidity and Capital Resources

We used the proceeds from the sales of common stock through September 30, 2007 and proceeds from notes and loans payable for working capital purposes and to fund our notes receivable of which we have \$1,010,549 owed to us at September 30, 2007. We will continue to advance funds under note agreements to providers that subscribe to our financial services lending solutions.

Edgar Filing: MDwerks, Inc. - Form 10QSB

From March 22, 2006 through September 28, 2006, we sold 28.3 units in a private placement to accredited investors pursuant to the terms of a Confidential Private Placement Memorandum, dated February 1, 2006, and private placement subscription agreements executed and delivered by each investor on or before the closing of the private placement. In connection with the sale of the 28.3 units, we received net proceeds of \$1,426,391.

On August 24, 2006, we received gross proceeds of \$250,000 (net proceeds of \$236,566, after expenses) in connection with a financing provided by an unrelated party. In connection with the financing, we issued a secured promissory note in the original principal amount of \$250,000 (the "Note") and a three year warrant to purchase 111,111 shares of our common stock at a price of \$2.25 per share. The Note bears interest at the rate of 7% per year, payable monthly in arrears and will become due and payable on August 24, 2007. This Note is subject to certain mandatory prepayment provisions as defined in the secured promissory note. At September 30, 2007, principal payments made under the mandatory prepayment provisions had reduced the Note balance to \$213,850. In connection with this note, our subsidiary, Xenii Financial, entered into a security and guaranty agreement whereby Xenii Financial has agreed to guaranty repayment of the note and grant a security interest in a client Revolving Line of Credit Loan Agreement including two promissory notes in the original principal amounts of \$250,000 and \$121,068 issued by that client to Xenii Financial, which were consolidated into a single promissory note in the amount of \$180,165 on December 5, 2006.

On August 24, 2006, we received gross proceeds of \$110,000 (net proceeds of \$100,000, after expenses) in connection with a financing provided equally by two unrelated parties. These notes bear interest at 10% per year, and both interest and principal were paid on the January 21, 2007 maturity date.

On each of October 20, 2006 and November 9, 2006 we received gross proceeds of \$2,500,000 (\$2,375,000 net proceeds) for a total of \$5,000,000 in the aggregate (\$4,750,000 net proceeds in the aggregate) in connection with a financing provided by Gottbetter Capital Master, Ltd., an unaffiliated accredited institutional investor.

On August 31, 2007 we received gross proceeds of \$250,000 in connection with a financing provided by Vicis Capital Master Fund, an unaffiliated accredited investor. In connection with the financing, we issued a Convertible Note to Vicis in the original principal amount of \$250,000.

On September 28, 2007 we received gross proceeds of \$2,000,000 (net proceeds of \$1,691,445 less repayment of the \$250,000 August 31, 2007 Vicis Capital Master Fund Convertible Note, interest and closing expenses) in connection with a financing provided by Vicis Capital Master Fund, an unaffiliated accredited institutional investor.

While we have sufficient funds to conduct our business and operations as they are currently undertaken into the next quarter, our ability to continue to implement our revenue and profit growth strategy beyond the next quarter will be adversely affected and the Company may have to curtail operations if we are unable to consummate a sufficient amount of additional private placement transactions or debt financing, which we are currently pursuing.

We currently have no material commitments for capital expenditures.

Cash flows

At September 30, 2007, we had cash of \$1,771,111.

Net cash used in operating activities was \$3,309,989 for the nine months ended September 30, 2007 as compared to \$2,270,394 for the nine months ended September 30, 2006, an increase of \$1,039,595. This increase is primarily attributable to an increase in our net loss and:

1. Gottbetter debt offering costs of \$133,500 and Gottbetter, Goldner and Grenier debt discount and debt issuance costs of \$1,208,594 and \$10,954, respectively, compared to debt related costs during the nine months ended

September 30, 2006 of \$31,913;

2. Stock-based compensation of \$2,506,281 versus stock-based compensation expense of \$1,878,572 for the nine months ended September 30, 2006 primarily related to issuance of stock options to employees;
3. No settlement expense versus settlement expense in the amount of \$180,827 for the conversion of \$40,000 of notes payable to common stock for the nine months ended September 30, 2006;

26

4. No loss on valuation of warrant liability versus loss on valuation of warrant liability of \$192,914 through September 30, 2006 due to the revaluation of our warrant liability to fair value;
5. No interest expense in connection with grant of warrants, versus interest expense of \$335,273 through September 30, 2006;
6. A net increase in notes receivable, accounts receivable and prepaid expenses aggregating \$537,541 principally related to the increase in funding of notes receivable to providers that subscribe to our MDwerks financial services solution;
7. An increase in accounts payable, accrued expenses, and deferred revenue related to an increase in operating activities aggregating \$244,457.

Net cash used in investing activities was \$5,209 for the nine months ended September 30, 2007 as compared to \$71,728 for the nine months ended September 30, 2006 and is principally related to the acquisition of computer and office equipment and furniture.

Net cash provided by financing activities was \$1,939,468 due to the proceeds from the sale of Series B Preferred Stock for the nine months ended September 30, 2007 as compared to net cash provided by financing activities of \$1,716,471 due to net proceeds from the sale of Series A Convertible Preferred Stock for the nine months ended September 30, 2006.

Off Balance Sheet Arrangements

We had no off balance sheet arrangements as of September 30, 2007.

Cautionary Language Regarding Forward-Looking Statements and Industry Data

This report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, many of which are beyond our control. Our actual results could differ materially and adversely from those anticipated in such forward-looking statements as a result of certain factors, including those set forth below and elsewhere in this report. Important factors that may cause actual results to differ from projections include, but are not limited to, for example:

- adverse economic conditions;
- inability to raise sufficient additional capital to implement our business plan;
- intense competition, including entry of newly-developed alternative drug technologies;
- unexpected costs and operating deficits, and lower than expected sales and revenue;
- adverse results of any legal proceedings;
- inability to satisfy government and commercial customers using our technology;
- the volatility of our operating results and financial condition;
- inability to attract or retain qualified senior management personnel, including sales and marketing, and technology personnel; and

other specific risks that may be alluded to in this report.

All statements, other than statements of historical facts, included in this report regarding our strategy, future operations, financial position, estimated revenue or losses, projected costs, prospects and plans and objectives of management are forward-looking statements. When used in this report, the words “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” “plan” and similar expressions are intended to identify forward-looking statements although not all forward-looking statements contain such identifying words. All forward-looking statements speak only as of the date of this report. We do not undertake any obligation to update any forward-looking statements or other information contained herein. Potential investors should not place undue reliance on these forward-looking statements. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements in this report are reasonable, no one can assure investors that these plans, intentions or expectations will be achieved.

Information regarding market and industry statistics contained in this report is included based on information available to us that we believe is accurate. It is generally based on academic and other publications that are not produced for purposes of securities offerings or economic analysis. We have not reviewed or included data from all sources, and we cannot assure investors of the accuracy or completeness of the data included in this report. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and the additional uncertainties accompanying any estimates of future market size, revenue and market acceptance of products and services. We have no obligation to update forward-looking information to reflect actual results or changes in assumptions or other factors that could affect those statements.

ITEM 3. CONTROLS AND PROCEDURES

We maintain “disclosure controls and procedures,” as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. We conducted an evaluation (the “Evaluation”), under the supervision and with the participation of our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operation of our disclosure controls and procedures (“Disclosure Controls”) as of the end of the period covered by this report pursuant to Rule 13a-15 of the Exchange Act. Based on this Evaluation, our CEO and CFO concluded that our Disclosure Controls were effective as of the end of the period covered by this report.

We have also evaluated our internal controls for financial reporting, and there have been no significant changes in our internal controls or in other factors that could significantly affect those controls subsequent to the date of their last evaluation.

Our management, including our CEO and CFO, does not expect that our Disclosure Controls and internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management or board override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. CEO and CFO Certifications appearing immediately following the signatures section of this report there are Certifications of the CEO and the CFO. The Certifications are required in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (the Section 302 Certifications). This Item of this report, which you are currently reading is the information concerning the Evaluation referred to in the Section 302 Certifications and this information should be read in conjunction with the Section 302 Certifications for a more complete understanding.

Evaluation of disclosure controls and procedures and remediation

In connection with the Restatement, under the direction of the Company's management, we have reevaluated certain disclosure controls and procedures and internal control over financial reporting. In connection with the Restatement, we identified a material weakness in our internal controls and procedures relating to the accounting treatment of our series A preferred stock and related warrants.

To our knowledge, as of the date of this filing, we have remediated such material weakness in our internal controls and procedures.

In connection with this Form 10-QSB, under the direction of our Chief Executive Officer, we have evaluated our disclosure controls and procedures as of September 30, 2007, including the remedial actions discussed above, and we have concluded that, as of September 30, 2007, our disclosure controls and procedures are effective.

It should be noted that while our management believe our disclosure controls and procedures provide a reasonable level of assurance, they do not expect that our disclosure controls and procedures or internal controls will prevent all error and all fraud. A control system, no matter how well conceived or operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments, in decision making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of internal control is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

PART II — OTHER INFORMATION

Item 1 — Legal Proceedings

None

Item 2 — Unregistered Sales of Equity Securities and Use of Proceeds

During the three months ended September 30, 2007, two Series A preferred stockholders' converted three shares of Series A Preferred Stock into 60,000 shares of common stock.

On September 28, 2007, the Company received gross proceeds of \$2,000,000 (net proceeds of \$1,691,445 after repayment of the \$250,000 31-day August 31, 2007 Convertible Note, interest and closing expenses) in connection with a financing provided by Vicis Capital Master Fund, an unaffiliated accredited institutional investor. In connection with the financing, pursuant to the terms of a Securities Purchase Agreement, we issued 200 shares of Series B Convertible Preferred Stock (a "Series B Preferred Stock"), a seven year Series F Warrant to purchase 1,500,000 shares of our common stock at a price of \$2.25 per share and a seven year Series G Warrant to purchase 1,000,000 shares of our common stock at a price of \$2.50 per share.

Item 3 — Defaults Upon Senior Securities

None.

Item 4 — Submissions of Matters to a Vote of Security Holders

None.

Item 5. Other Information

None

Item 6. Exhibits

| | |
|------|----------------------------------------------------------|
| 31.1 | Section 302 Certification of Principal Executive Officer |
| 31.2 | Section 302 Certification of Principal Financial Officer |
| 32.1 | Section 906 Certification of Principal Executive Officer |
| 32.2 | Section 906 Certification of Principal Financial Officer |

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MDWERKS, INC.

November 13, 2007

/s/ Howard B. Katz

Howard B. Katz
Chief Executive Officer

November 13, 2007

/s/ Vincent Colangelo

Vincent Colangelo
Chief Financial Officer